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A growing number of diseases are associated with inappropri-ate depositions of protein aggregates, especially neurological disorders and systemic amyloidoses1. During malignancy, 
proteins are usually uncontrollably overexpressed or structurally 
affected because of genetic mutations, resulting in changes in activ-
ity and protein-protein interactions in cancer cells2. It remains, how-
ever, largely unexplored whether aggregation of tumor suppressors 
and/or oncogenes could contribute to the induction or progression 
of malignancy.
The tumor suppressor p53 is a key regulator of the cell cycle 
and is mutated in ~50% of reported human tumor cases, making 
it a major target for anticancer therapy3. p53 is a transcription fac-
tor that acts as a homotetramer, with each monomer consisting 
of an N-terminal transactivation domain, a proline-rich domain, 
a central DNA-binding domain, a tetramerization domain and a 
C-terminal regulatory domain (Fig. 1a). According to IARC TP53 
Mutation Database4, over 95% of the malignant mutations occur in 
the DNA-binding domain, where they cluster in so-called hot spots 
of mutation.
Previously, it has been shown that the DNA-binding domain of 
p53 is conformationally unstable and that the majority of hot-spot 
disease mutants such as R175H, R282W, R248Q and R249S further 
destabilize the DNA-binding domain5 (Fig. 1a). Consequently, a 
proportion of these mutants are at least partially unfolded6 and 
therefore inactive. These mutants, present in about 30% of reported 
clinical cases7, are usually referred to as ‘structural’ mutants. A sec-
ond class of disease mutants, such as R273H and R248W, which 
are present at the p53 DNA-binding interface, affect DNA binding 
without affecting the conformational stability of the domain and 
are therefore referred to as ‘contact’ mutants, representing about 
20% of cases. In spite of these previous findings, it remains unclear 
how dominant-negative activity and gain of oncogenic function 
emerge from these structural defects.
As native p53 functions as a tetrameric protein, it is generally 
accepted that the dominant-negative effect arises from the incor-
poration of both inactive mutant and wild-type p53 molecules into 
mixed tetramers, resulting in a reduced cellular concentration of 
functional p53 (ref. 8).
Several biological mechanisms leading to gain of tumorigenic 
function of p53 mutants have been proposed9, and one pivotal 
mechanism seems to be the ability of mutant p53 to interact with 
and attenuate the function of its paralogs p63 and p73, whose 
transactivating isoforms have been demonstrated to inhibit tumor 
metastasis and increase the sensitivity for radiochemotherapy10,11. 
Although this mechanism involves tetramer-independent inter-
actions between the DNA-binding domains of p53 and its paralogs, 
the exact mechanism of interaction also remains unexplained12,13.
Here we report that the dominant-negative activity and gain-of-
function effects of structurally destabilized p53 mutants result from 
their increased aggregation propensity. Upon its aggregation, mutant 
p53 not only induced misfolding and coaggregation of wild-type p53 
but also of its paralogs p63 and p73 into cellular inclusions, caus-
ing deficient transcription of target genes involved in cell growth 
control and apoptosis. In analogy to what is observed in aggregation-
 associated diseases, we therefore propose that the dominant-negative 
activity and gain of function of structurally destabilizing p53 mutants 
directly result from their increased aggregation propensity.
RESULTS
Structurally destabilized p53 mutants aggregate in vitro
To investigate the effect of contact and structural mutations in 
p53 on its cellular distribution, we first transiently overexpressed 
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wild-type and mutant p53 in the human osteosarcoma SaOS-2 cell 
line, which is devoid of endogenous p53. Immunofluorescence 
revealed a predominant nuclear distribution of wild-type p53 and 
of the DNA-contact mutants R248W and R273H. In contrast, p53 
mutants R175H, R282W, R249S, R248Q, P250L, E258V, R110L 
and R110P showed reduced nuclear staining, with a compensa-
tory increase of cytoplasmic staining (Fig. 1b; Supplementary 
Results, Supplementary Figs. 1 and 2a,b), with the latter regularly 
containing ‘punctate’ cytoplasmic spots. A punctate staining sug-
gested the assembly of mutant p53 into large aggregates within the 
perinucleus and was consistent with an impaired nuclear import 
of p53 (ref. 14).
To further investigate the aggresomal nature of the observed 
inclusions, several strategies were adopted. As the formation of 
cytoplasmic inclusions in aggresomes is an active process that 
depends on cytoskeletal integrity15, transfected cells were treated 
with nocodazole, a small chemical that disrupts microtubule assem-
bly. Indeed, after nocodazole treatment, the cellular distribution of 
mutant p53 shifted from a punctate to a diffuse cytoplasmic stain-
ing, thereby confirming the aggresomal nature of these inclusions 
(Fig. 1b). In addition, we also assessed the oligomerization state of 
p53 in SaOS-2 cells by Blue-Native PAGE (BN-PAGE) and west-
ern blot analysis, after cell lysis with a mild detergent (CHAPS). 
In agreement with previous reports16, transiently overexpressed 
wild-type p53 appeared as monomers, tetramers and octamers 
on western blots, and an identical pattern was also observed for 
the DNA-contact mutants R248W and R273H (Supplementary 
Fig. 2c). However, overexpression of the aggregating mutants 
R175H, R282W, R248Q, R249S, P250L, E258V, R110L and R110P 
caused a shift in molecular mass ranging from 800 kDa up to the 
fractionation limit of the gel (10,000 kDa), consistent with the for-
mation of large multimeric assemblies (Supplementary Fig. 2c). 
In denaturing but nonreducing PAGE, the oligomers and aggregates 
were dissociated into monomers, and all mutants were expressed at 
similar levels (Supplementary Fig. 2d).
Analysis of the aggregation propensity of p53
To better understand why structurally destabilized mutations in 
p53 would induce aggregation, we used TANGO17, an algorithm 
for predicting protein aggregation sequences, to identify regions 
in the protein that would be prone to aggregation. Here we iden-
tified an aggregation-nucleating segment that spans residues 251 
to 257 in the hydrophobic core of the p53 DNA-binding domain. 
In the native structure, these residues form a β-strand that is an 
integral part of the hydrophobic core of the p53 DNA-binding 
domain (Fig. 1a). Mutations that destabilize the tertiary structure 
of the DNA-binding domain are therefore likely to increase the 
exposure of regions that are normally buried in the hydrophobic 
core18, such as the aggregation-nucleating region, and therefore also 
prone to trigger aggregation of the p53 protein by assembly of the 
 aggregation-nucleating stretch into an intermolecular β-sheet–like 
structure (Supplementary Fig. 3).
To retrieve information on the secondary-structure content of 
the p53 mutants, Fourier transform infrared (FTIR) spectrometry 
(Supplementary Methods) was performed. Hemagglutinin-tagged 
p53 (HA-p53) was transiently overexpressed and immunopurified 
from SaOS-2 cells. Difference spectra showed that contact mutants 
such as R273H had a wild-type conformation, whereas aggregating 
mutants such as P250L, E258V and R110L had increased absorbance 
around 1,615 and 1,683 cm−1, consistent with an increase in inter-
molecular β-sheet structure (Supplementary Fig. 4a). In addition, 
when we used recombinant p53 DNA-binding domain, produced in 
E. coli, the aggregates formed had an amorphous macromolecular 
structure as judged by electron microscopy (Supplementary Fig. 4b) 
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Figure 1 | Structure of p53 protein and the effects of mutations on protein cellular localization. (a) The schematic domain structure of p53 is shown in 
the upper panel. an aggregation-prone sequence sits in the DNa-binding domain, spanning the residues 251 to 257. mutations that can inhibit aggregation 
(I254R) or abolish tetramerization (l344P) are labeled in red. The structure of p53 DNa-binding domain is shown in the lower panel. The structural 
mutations (R110P, R175H, R248Q, R249S and R282W) and the contact mutations (R248W and R273H) are labeled in red and green, respectively. The 
aggregation-prone sequence is shown in yellow. (PDB ID: 1TUP, image generated by vmD software, http://www.ks.uiuc.edu/). (b) The Do-1 antibody 
revealed intense punctate cytoplasmic staining (white arrows) for the structural mutants R175H and R282W but not the contact mutant R273H and the 
wild-type p53. The cytoplasmic aggregates were caged by collapsed vimentin, and the treatment with nocodazole produces a diffuse cytoplasmic staining 
for the aggregating mutants. Scale bars: 10 μm.
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and were enriched in intermolecular β-interactions as judged by 
FTIR analysis (Supplementary Fig. 4c). These results are consistent 
with previous findings19 and support the notion that p53 mutants 
assemble into higher-order polymers through β-aggregation.
To confirm that residues 251–257 act as an aggregation nucleus, 
we used several strategies. First, digesting the aggregates formed 
by the recombinant p53 DNA-binding domain with proteinase K 
resulted in a proteolytic cleavage product that retained an amor-
phous morphology (Supplementary Fig. 4d) with intermolecular 
β-structure but was depleted of other regular secondary structure 
(Supplementary Fig. 4e). Subsequent electrospray ionization– 
mass spectrometry (ESI-MS) analysis yielded peptide fragments 
covering residues 252–256, thereby confirming the incorpora-
tion of these residues in the core of the aggregates. Second, we 
transfected fluorescently labeled peptides encompassing residues 
251–257 in SaOS-2 cells and found that they accumulated in peri-
nuclear inclusions (Supplementary Fig. 5a). Equally, we overex-
pressed N-terminal fusions of this same peptide to GFP and again 
found punctuate inclusion formation (Supplementary Fig. 5b). 
These experiments show that residues 251–257 have a strong 
aggregation propensity and are sufficient to induce aggregation of 
an entire protein.
Interfering with the aggregation propensity of p53
To further reveal the significance of this aggregating zone, we per-
formed an in silico analysis using TANGO, searching for additional 
mutations that would abrogate the aggregation propensity of that 
zone. Several mutations with such characteristics were identified 
and introduced into the p53 expression vectors. An example of a 
place for such a mutation is residue 254, present in the middle of 
the aggregation nucleus, which we mutated from a hydrophobic to 
a positive charge (I254R) (Supplementary Fig. 5c). By introduc-
ing this additional mutation, we expected to suppress aggregation 
of these p53 mutants.
Indeed, when analyzing the double mutant p53E258V/I254R and 
p53R175H/I254R proteins on BN-PAGE after transient overexpression in 
SaOS-2 cells, we found that both failed to aggregate; instead, they were 
efficiently degraded, as indicated by the significant reduction in over-
all mutant protein levels compared to the wild type (Supplementary 
Fig. 5d). Notably, even when we protected these double mutants 
from degradation by adding a proteasomal inhibitor (20 μM 
MG-132) to the medium, these mutants still did not aggregate into 
high– molecular weight bands but instead accumulated as misfolded, 
soluble p53 (Supplementary Fig. 5d). Consistently, the I254R muta-
tion also inhibited the aggregation of the p53 (251–257)-GFP fusion 
protein, resulting in a homogenous distribution of the protein within 
the cell (Supplementary Fig. 5e). On the contrary, another designed 
mutation, T256R, which partially alleviates but does not suppress the 
aggregation propensity of the protein, did not suppress the aggrega-
tion of mutant p53, suggesting the critical role of residues 251–257 in 
nucleating aggregation (Supplementary Fig. 6).
Aggregation of destabilized p53 mutants in human tumors
To exclude the possibility of artifacts from overexpression, tumor 
cell lines carrying endogenous mutant p53, including MOG-G-
CCM (p53 R110P) astrocytoma, HT-1376 (p53 P250L) bladder 
carcinoma, Detroit 562 (p53 R175H) pharynx carcinoma and 1301 
(p53 R282W) T-cell leukemia, were analyzed for their cellular dis-
tribution of p53. Comparable to the overexpression of most mutant 
p53 proteins in SaOS-2 cells (see above), a marked punctate staining 
was observed that accumulated throughout the perinucleus. In con-
trast, a homogeneous nuclear distribution of endogenous p53 was 
observed in U-2 OS osteosarcoma cells (p53 wild type) and WiDr 
(p53 R273H) colon carcinoma (Fig. 2a,b), as in previous reports20.
Notably, these inclusions stained positive with Thioflavin T, 
a fluorescent dye that binds preferentially to β-aggregates (Fig. 2a), 
indicating that the large inclusions were indeed formed by 
 aggregation. Accordingly, BN-PAGE analysis revealed an increased 
molecular weight of the endogenous p53 in the mutant cell lines 
MOG-G-CCM, HT-1376, Detroit 562 and 1301 but not in the U-2 OS, 
WiDr and Ramos Burkitt’s lymphoma (p53 I254D) cell lines 
(Supplementary Fig. 7a,b). Consistently, cytoplasmic p53 was also 
found in tumor cells derived from heart, kidney and thymus lym-
phomas from a knock-in mouse model expressing p53 R172H, the 
mouse equivalent of human mutation R175H13 (Fig. 2c).
Finally, a blind screen of samples from ten colorectal adeno-
carcinomas yielded a single case carrying a point mutation in the 
DNA-binding domain (R282W). Consistent with our results from 
cultured cell lines, immunofluorescence revealed cytoplasmic inclu-
sions of p53 but no nuclear staining in the mutant sample (Fig. 2d 
and Supplementary Table 1). In contrast, no inclusions were found 
in tumor samples from patients not carrying an aggregating muta-
tion (Supplementary Fig. 7c).
Structural p53 mutants coaggregate with wild-type p53
To investigate whether the higher aggregation propensity of mutant 
p53 can lead to coaggregation of wild-type p53, we performed cotrans-
fection experiments into SaOS-2 cells of HA-tagged mutant p53 
and Flag-tagged wild-type p53. Immunofluorescence showed cyto-
plasmic retention and colocalization of both wild-type and mutant 
p53 within aggregates (Supplementary Fig. 8). Also in BN-PAGE, 
wild-type p53 aggregated and comigrated with mutant p53 upon 
cotransfection (Fig. 3a). Coimmunoprecipitation experiments of 
mutant HA-p53 from cell lysates showed tetramerization-indepen-
dent interaction between aggregating mutant– and Flag–wild-type 
p53 (Fig. 3b, full-gel images in Supplementary Fig. 9). Consistent 
with our previous observations, this interaction was also abolished 
in the presence of the I254R mutation (Supplementary Fig. 10a). 
Similarly, the introduction of positive or negative charges (I254D, 
I255R and I255D) also prevented mutant p53 from aggregating and 
interacting with wild-type p53 (Supplementary Fig. 10b–e). This 
observation was specific for the aggregation-nucleating region, as 
the introduction of charges outside this zone did not prevent mutant 
p53 (co)aggregation (Supplementary Fig. 11a,b).
To determine whether forced cytoplasmic localization caused by 
a deficient nuclear localization signal (NLS) in p53 could induce 
aggregation of p53, we introduced the K305N mutation that prevents 
binding of p53 to the NLS receptor (Supplementary Fig. 11c)21. The 
resulting NLS mutant did not aggregate (Supplementary Fig. 11d), 
thereby suggesting that the aggregation of p53 is mutation specific, 
rather than dependent on the subcellular localization.
Aggregation-dependent dominant-negative effects
To validate the concept of dominant-negative activity of mutant-
induced wild-type p53 aggregation, we monitored the transcrip-
tional activity of p53 using a PG-13 luciferase reporter plasmid 
containing 13 contiguous p53 DNA-binding sites in SaOS-2 cells 
that were transfected with wild-type and/or mutant p53. We also 
performed reverse transcriptase quantitative PCR (RT-qPCR) on 
four endogenous p53-regulated genes, namely mdm2, bax, cdkn1a 
(encoding p21) and noxA22. As compared to overexpression of 
wild-type p53 alone, expression of mutant p53 showed dramati-
cally reduced luciferase activity (Supplementary Fig. 12a), con-
firming the cells’ loss-of-function phenotype. More notably, the loss 
of luciferase activity and target gene expression was also observed 
upon cotransfection of wild-type and aggregating mutant p53, con-
firming the dominant character of these disease-related mutations 
(Supplementary Fig. 12b).
As previously mentioned, it is largely accepted that dominant-
negative activity results from the incorporation of mutant p53 
into mixed tetramers7. However, our results suggest that the dom-
inant-negative action of conformationally destabilized mutants 
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(more than 30% of reported cases) is exerted through mutant-
induced coaggregation. If the former mechanism is correct, 
dominance should be strictly dependent on the tetramerization 
domain. However, if dominance is aggregation-driven, it should 
also be dependent on the aggregation-nucleation sequence span-
ning residues 251 to 257.
To distinguish between these two possibilities, we modified 
aggregating and contact mutants with secondary mutations that 
suppress tetramerization, aggregation or both. To probe tetramer-
ization, we generated p53 mutants that carry both a disease-causing 
mutation and the tetramerization-suppressing mutation L344P23. To 
probe aggregation, we also generated mutant p53 that carries both a 
disease-causing mutation and the aggregation-suppressing mutation 
I254R. Finally, as a control, we generated triple mutants combin-
ing the disease mutation, the tetramerization-suppressing mutation 
and the aggregation-suppressing mutation. The dominant-negative 
activity of these mutants was subsequently tested for their interac-
tion with and dominant-negative effect on wild-type p53.
First, we assessed the ability of contact mutants R273H and 
R248W to inhibit p53-induced expression of MDM2, BAX, p21 and 
NOXA upon coexpression with the wild-type p53 in SaOS-2 cells. 
This inhibition was alleviated upon suppression of tetramerization 
through the L344P mutation, whereas the  aggregation-suppressing 
mutant I254R had no effect (Supplementary Fig. 12c), 
 demonstrating that the dominant- negative activity of contact 
mutants is indeed exerted strictly through tetramerization. In 
contrast, however, the dominant-negative activity of aggregation-
prone mutants E258V and R282W was reduced but not abro-
gated when tetramerization was suppressed through the L344P 
mutation. To completely abrogate the dominance of the aggre-
gating mutations, it was necessary to also suppress their aggre-
gation propensity by including the additional I254R mutation 
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Figure 2 | Immunostain of p53 aggregates in tumor cell lines and tissues. (a) The mutant p53 in HT-1376 bladder carcinoma (P250l), moG-G-CCm 
astrocytoma (R110P) and Detroit 562 pharynx carcinoma (R175H) showed a marked punctate staining of p53, equally accumulating in perinuclear loci, 
whereas the endogenous wild-type p53 in U-2 oS osteosarcoma and the contact mutant R273H in WiDr colon carcinoma cells showed homogenous 
nuclear distribution. The cytoplasmic aggregates were found to stain for Thioflavin T (green), a fluorescent dye that binds preferentially to β-aggregates 
(white arrows). (b) Statistical analysis of p53 localization in cell lines, showing the percentage of cells with predominantly nuclear staining. Data represent 
mean values ± s.d. (n = 3). ***P < 0.001 (Student’s t-test). WT, wild type. (c) Immunostain of lymphoma tissue in a p53R172H/R172H transgenic mouse 
model. p53 was only detected in the punctuate cytoplasmic structures, suggesting the aggregation of R172H mutant in these tissues. (d) In human colon 
adenocarcinoma tissue that carried p53 destabilized mutation R282W, p53 was detected in cytoplasmic inclusions. Scale bar: 10 μm.
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(Supplementary Fig. 12d). This  tetramerization-independent 
interaction was confirmed by coimmunoprecipitation: although 
both contact and aggregating p53 mutants with an intact tetrameri-
zation domain precipitated together with wild-type p53, only the 
subset of aggregating p53 mutants was still able to interact with 
wild-type p53 when the L344P mutation was present (Fig. 3b). Only 
the loss of the aggregation propensity caused by the I254R muta-
tion (Supplementary Fig. 10a) alleviated the interaction of aggre-
gating mutants with wild-type p53. BN-PAGE further confirmed 
that introduction of the L344P mutant converted wild-type p53 as 
well as the contact mutant R273H and R248W into p53 monomers. 
In contrast,  aggregating p53 mutants R282W and E258V still 
formed large aggregates in the presence of the L344P mutation and 
did not show a monomer band in BN-PAGE, whereas wild-type p53 
still comigrated as high–molecular weight species (Supplementary 
Fig. 12e). Together these data indicate that, contrary to contact 
mutants, the dominance of structurally destabilized mutants origi-
nates from their increased aggregation propensity.
To exclude the idea that the suppressive effect of the I254R 
mutant results from increased mutant degradation rather than from 
a suppression of its aggregation propensity, we also measured the 
effect of the I254R and L344P mutants on the dominance of  disease 
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Figure 3 | Mutant p53 induced coaggregation of wild-type p53 and caused dominant-negative activity. (a) BN-PaGE of mutant p53 (upper panel) and 
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higher molecular weight and comigrated with the mutant. (b) Coimmunoprecipitation of Ha-tagged mutant p53 and the Flag-tagged wild-type p53. Physical 
interaction between wild-type p53 and all mutants with intact tetramerization domain occurred (upper panel), but only the aggregating mutants were still 
able to bind the wild type when heterotetramerization was inhibited by the l344P mutation (lower panel). (c) qPCR assay showing a dominant-negative 
effect of R273H that is strictly dependent on heterotetramerization. In all qPCR assays, data represent mean values ± s.d. (n = 4). (d) Coimmunoprecipitation 
revealed that the interaction between R273H and wild type was abolished by l344P mutation but not by I254R mutation. (e) qPCR showing transactivity 
of coexpressed wild-type and mutant p53. The wild-type transactivity was inhibited by R175H mutant, whereas the introduction of I254R mutation rescued 
wild-type function. *P < 0.05; **P < 0.01 (Student’s t-test). (f) The interaction between R175H and wild-type p53 was abolished by I254R mutation. (Uncut, 
full-gel images of panels b, d and f are shown in Supplementary Fig. 9.) IP, immunoprecipitation; WB, western blot.
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mutants in the presence of the proteasomal inhibitor MG-132. 
Under these conditions the ability of the contact mutant R273H 
to interact with wild-type p53 and to interfere with p53-induced 
expression of MDM2, BAX, p21 and NOXA upon coexpression 
with the wild-type p53 in SaOS-2 cells was again strictly dependent 
on tetramerization (Fig. 3c,d).
The dominant-negative activity of the aggregating mutant R175H 
again showed a more complex behavior than the contact mutant and 
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Figure 4 | Sequestration of p63 and p73 by mutant p53 aggregates. (a,b) although coexpression of wild-type p53 and p73 and p63 resulted in 
homogeneous nuclear staining of the proteins, the p53 mutants R282W and R110P formed perinuclear aggregates and sequestered p73 (a) and p63 (b) 
in the cytoplasm (white arrows). (c,d) Three-dimensional (3D) confocal microscopy revealed the morphology of large aggregates formed by p73 (c) and 
p63 (d) in the perinuclear regions. (e) In lymphoma in kidney of p53R172H/R172H mouse, p73 was found in punctuate cytoplasmic structures, colocalizing with 
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could only be abrogated when both tetramerization and aggregation 
were suppressed simultaneously (Fig. 3e). Coimmunoprecipitation 
and BN-PAGE of wild-type p53 with the R175H mutant in the 
presence of the proteasomal inhibitor MG-132 further confirmed 
these effects. Coprecipitation of wild-type p53 with R175H could 
only be abrogated when both tetramerization and aggregation were 
suppressed (Fig. 3f). Wild type was precipitated with the mutant, 
however, only when either tetramerization or aggregation were sup-
pressed. Moreover, BN-PAGE showed a clear difference in the oligo-
merization state of the precipitated wild-type p53 in both cases. 
Whereas wild-type p53 forms high–molecular weight aggregates 
in the presence of the tetramer-incompetent R175H/L344P, wild-
type p53 remains tetrameric in the presence of the aggregation-
 incompetent R175H/I254R (Supplementary Fig. 13a,b).
Together, these data demonstrate that the dominant- negative 
effect of structurally destabilized mutants is determined by aggre-
gation and that the tetramerization domain cooperates with 
the aggregation-nucleating region to coprecipitate wild-type p53 
into aggregates.
p53 aggregation inactivates p63 and p73 by coaggregation
As already mentioned above, a pivotal mechanism in the tumori-
genic characteristics of mutant p53 is to interact with and attenu-
ate the function of its paralogs p63 and p73. These are members of 
the p53 gene family (63% identity of p53 with p73, and 60% of p53 
with p63), and their transactivation isoforms have partial  functional 
 overlap with p53. Although p63 and p73 are rarely mutated in 
tumors, their functions are frequently inhibited by mutant p53, lead-
ing to an increase in oncogenic potential of the affected cells13,24.
Inactivation is probably achieved by direct interactions between 
mutant p53 and its paralogs that involve interactions between the 
proteins’ DNA-binding domains whose mechanism is still unde-
termined25. As a result of a low structural conservation of their 
tetramerization domains, p53 and its paralogs cannot tetramer-
ize, and therefore the interaction should be tetramer indepen-
dent26. Using TANGO, we found that p53, p63 and p73 have highly 
conserved aggregating sequences in the same structural motif 
(Supplementary Fig. 14a). As coaggregation of proteins depends 
strictly on sequence similarity rather than hydrophobicity27, mutant 
p53 might also be able to induce coaggregation and inactivation 
of p63 and p73. To investigate this hypothesis, we coexpressed 
mutant p53 and the transactivation domain (TA) of p63 or p73 
(TAp63α/TAp73α) in SaOS-2 cells. In the presence of wild-type 
p53, both p63 and p73 predominantly localized to the nucleus; in 
contrast, coexpression of aggregating p53 mutants (R282W and 
R110P) with TAp63α/TAp73α drove p63 and p73 into perinuclear 
aggregates (Fig. 4a–d). The aggregates of mutant p53, p63 and p73 
showed strong colocalization inside vimentin-caged aggresomes. 
Addition of nocodazole disrupted the vimentin network and resulted 
in diffused punctuate aggregates in the cytoplasm (Supplementary 
Figs. 14b and 15a,b), confirming the aggresomal colocalization of 
aggregated p53 and its paralogs. Coexpression with the p53 NLS 
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Figure 5 | Mutant p53 interacted and interfered with p73 through coaggregation. (a) Coimmunoprecipitation of mutant p53 and p73 overexpressed 
in SaoS-2 cells. The structurally destabilizing mutants R110P, R175H and R282W showed strong interaction with p73, which was not observed for wild-
type p53 and contact mutant R273H. The aggregation-suppressive mutations of p53 (I254R) and p73 (I274R) disrupted the interaction between mutant 
p53 and p73. (b,c) The coexpression of p53 aggregating mutant R175H significantly inhibited the transactivity of p73 on p53-responsive genes (b) and 
Jun-B and p57kip2 (c), whereas the introduction of I254R mutation into p53 R175H, in both absence and presence of mG-132, successfully abolished its 
interference with p73 functions. Data represent mean values ± s.d. (n = 4). **P < 0.01 (Student’s t-test). (d) overexpression of the aggregating mutant 
R175H induced substantial responses of Hsp90 and Hsp70. The introduction of I254R and I254D mutations reduced heat-shock response caused 
by R175H mutant. (e) The mRNa encoding Hsp70 was upregulated upon the expression of aggregating mutant R175H, whereas the I254R mutation 
abolished this effect. (Uncut, full gel images of panels c and f are shown in Supplementary Fig. 9.)
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mutant K305N (see above) did not alter the localization of p63 and 
p73 (Supplementary Fig. 15c), demonstrating that subcellular 
localization of p53 per se is not sufficient to retain p63 and p73 in 
the cytoplasm.
BN-PAGE showed that in the presence of wild-type p53 or 
contact mutants (R248W, R273H), native p63 and p73 existed as 
monomers, tetramers and octamers (Supplementary Fig. 16a,b). 
In the presence of aggregating p53 mutants (R110L, E258V, R175H, 
R282W and R249S), p63 and p73 instead formed large aggregates.
Immunofluorescent labeling of p53 and p73 in kidney lymphoma 
of p53R172H/H transgenic mice, as well as in liver and lung metastasis 
of osteosarcoma in p53R172H/+ mice, showed that p73 colocalized with 
p53 in cytoplasmic inclusions (Fig. 4e and Supplementary Fig. 16c). 
Consistently, in human colon carcinoma tissues carrying p53 mutant 
R282W, p73 also colocalized with p53 in cytoplasmic inclusion aggre-
gates (Fig. 4f, control staining shown in Supplementary Fig. 17).
To examine the role of the aggregating sequences of p53 (251–257), 
p63 (321–327) and p73 (271–277) in the interaction and aggrega-
tion of p53 with p63 and p73, the aggregation-suppressing muta-
tions p53 (I254R), p63 (I324R) and p73 (I274R) were analyzed by 
coimmunoprecipitation. Upon coexpression in SaOS-2 cells, contact 
mutants R273H and R248W interacted only very weakly with p63 
and p73 (Fig. 5a and Supplementary Fig. 18a); this was in contrast 
to the aggregating p53 mutants R175H, R282W and R110P that 
strongly interacted with p63 and p73. Introduction of aggregation-
 suppressing mutations completely abolished the interaction between 
p53 and its paralogs. Likewise, p63 I324R and p73 I274R did not 
interact with p53 R282W (Fig. 5a and Supplementary Fig. 18a).
We also addressed the role of mutant p53 aggregation on the 
functional inactivation of p63 and p73 by measuring their trans-
activation activity on the expression of MDM2, p21 and BAX by 
RT-qPCR. Although expression of p63 or p73 solely induced the 
expression of the different reporter genes, coexpression with the 
p53-aggregating mutant R282W substantially inhibited p63 and p73 
function (Fig. 5b and Supplementary Fig. 18b). Notably, suppres-
sion of the aggregation propensity of p53 R282W by introduction of 
the I254R mutation restored the transcriptional activity of p63 and 
p73, showing that coaggregation with mutant p53 is responsible for 
their inactivation (Fig. 5b and Supplementary Fig. 18b). To exclude 
any functional overlap with p53, we also tested the effect of p53 
mutants on genes that are exclusively regulated by p73. Expression 
of p57Kip2 and Jun-B28,29, which regulate p53-independent apopto-
sis pathways, was increased by p73; this increase was substantially 
inhibited upon coexpression with the p53 R282W mutant. Again, 
suppression of aggregation in p53 R282/I254R fully restored p73 
function (Fig. 5c). To exclude the possibility that the loss of activity 
observed for the I254R variants results from proteasomal degrada-
tion rather than a suppression of their aggregation propensity, the 
qPCR experiments were repeated in the presence of MG-132 and 
yielded similar results (Fig. 5b and Supplementary Fig. 18b).
These results demonstrate that the gain-of-function activity of 
structurally destabilized mutants results from their increased aggre-
gation propensity, allowing them to coprecipitate p63 and p73 into 
inactive cellular inclusions.
p53 aggregation upregulates hsp70 and hsp90
Heat-shock proteins are frequently found to be overexpressed in 
a wide range of tumors, and members of several chaperone fami-
lies have been demonstrated to promote tumor cell proliferation 
and inhibit cellular death pathways30. As protein denaturation 
and aggregation are powerful triggers of heat-shock response, the 
accumulated p53 aggregates may acquire antiapoptotic properties 
through the activation of heat-shock proteins. To study the effect 
of p53 aggregates on the expression level of two important cancer-
related chaperones Hsp70 and Hsp90 (ref. 31,32), we overexpressed 
wild-type and mutant p53 in the SaOS-2 cells and examined chap-
erone levels by western blot and qPCR. Although overexpression of 
the contact mutant R273H resulted in chaperone levels similar to 
those seen with wild-type p53, overexpression of the aggregating 
mutant R175H induced a substantial upregulation of both Hsp70 
and Hsp90 (Fig. 5d,e). Suppression of the aggregation propensity 
in the disease mutant R175H by the additional mutations I254R or 
I254D restored wild-type chaperone levels.
p53 aggregation, loss of heterozygosity and patient survival
We further analyzed whether aggregation of mutant p53 leads to 
stronger dominant-negative effect and lower survival rate in human 
tumors. If the wild-type p53 allele is strongly inhibited by the 
mutant, a lower rate of loss of heterozygosity should be observed. 
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Figure 6 | Aggregation of mutant p53 is linked to lower rate of loss of 
heterogeneity and patient survival. (a) analysis on the p53 germline 
mutation database revealed a significantly higher rate of p53 loss of 
heterogeneity in tumors carrying DNa contact mutations (64.5%), 
compared to those carrying structural mutations (37.3%). **P < 0.01 
(Chi-square test). (b) In two large-scale studies on prognosis of breast 
and colon cancers, the end point survival of patients with DNa-contact 
mutations was significantly higher than those carrying aggregating 
mutations34,35. **P < 0.01 (Chi-square test).
Homo β-aggregates
a b
c
Hetero β-aggregates
p63/73
tetramerization
domain
Mut p53 + p63/p73
Gain of function
Mut + WT p53
Loss of function
Synergy between tetramerization
and β aggregation
p53
tetramerization
domain
Misfolded
DNA-binding
domain
Correctly folded
DNA-binding
domain
Mutation
Figure 7 | Schematic graph showing the proposed model for 
coaggregation of p53, p63 and p73. (a) Structurally destabilized p53 
mutants form large aggregates and induce the coaggregation of the  
wild type, explaining the potentiation of the dominant negative effect.  
(b) Similar aggregation-prone sequences mediate the coaggregation of 
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formed by the structurally destabilized p53 mutants.
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Consistently, analysis of the p53 germline mutation database (129 
cases)33 revealed that tumors that carry DNA contact mutations 
show an approximately twofold higher rate of loss of heterozygosity 
than those with destabilized mutations (P < 0.01, Fig. 6a). The lower 
selective pressure for loss of the remaining wild-type p53 allele in 
destabilized germline mutations suggests a stronger dominant-
negative effect of structurally destabilized aggregating mutants. 
When we compiled independent studies on patient survival 
(623 cases)34,35, we found that the patient’s long-term survival was 
significantly higher for contact mutants than for aggregating 
mutants (P < 0.01, Fig. 6b). The poorer prognosis of patients carry-
ing aggregating mutants supports our model that p53 mutants gain 
oncogenic function through aggregation.
DIScUSSION
Wild-type p53 is a tumor suppressor that is crucial for protection 
against cancer. Accordingly, approximately half of human tumors 
harbor inactive p53 mutants. In addition, mutant p53 accumulates 
excessively in tumors and develops dominant-negative activity as 
well as wild-type–independent gain-of-function effects that con-
tribute to cancer development. Hence, whereas wild-type p53 is a 
tumor suppressor, cancer-associated mutations transform p53 into 
a potent oncogene.
The biochemical effects leading to gain of function are highly 
diverse, including suppression of p63 and p73 function, coopera-
tion with Ras in transformation, NF-κB activation and inhibition 
of autophagy9. The majority of these mutations, however, consist 
of simple missense mutations of which the majority accumulate in 
six hot-spot codons within the DNA-binding domain of p53. It is 
therefore surprising that such minor sequence alterations have such 
radical consequences.
Here we show that the functional conversion of p53 from a 
tumor suppressor to an oncogene by structurally destabilizing 
p53 mutations results from the increased aggregation propensity 
of these mutants, which is mainly achieved by exposing an aggre-
gation-nucleating sequence stretch from the hydrophobic core of 
the DNA-binding domain. Exposing this aggregation-nucleation 
sequence by structural destabilization of the DNA-binding domain 
triggers coaggregation of wild-type p53 into cellular inclusions, 
thereby abrogating wild-type activity and explaining the dominant-
negative behavior of the mutant. Notably, coaggregation is not 
only confined to wild-type p53. Indeed, we could demonstrate that 
structurally destabilized p53 mutants also coaggregate with the p53 
family members p63 and p73, thereby explaining its gain-of-func-
tion activity36 (Fig. 7). Finally, we showed that p53 aggregates lead 
to increased expression of heat-shock proteins, in particular Hsp70, 
a known antiapoptotic agent.
The identification of the above mechanism for mutant p53 dom-
inance and gain of function by protein aggregation unifies previ-
ously well known but poorly connected observations and provides 
a new angle for the understanding and possible treatment of p53 
transformation in cancer. Misfolding of destabilized p53 mutants 
was demonstrated 20 years ago by the binding of a conformation-
ally specific monoclonal antibody that recognizes a cryptic epitope 
not displayed by wild-type p53 (ref. 6). This is consistent with the 
higher affinity of these mutants for the chaperone Hsc70 (ref. 37). 
It was also immediately recognized that mutant p53 can induce this 
conformational modification in wild-type p53 by oligomerization38. 
However, as it was found that p53 binds DNA as a tetramer39, it has 
been accepted that dominant-negative inactivation of wild-type p53 
results from tetramerization7,40. Another string of evidence, linking 
the importance of conformational modifications in p53 mutants 
with their oncogenic behavior, emerged from the discovery of p53 
family members p63 and p73. Indeed, mutant p53, but not wild-type 
p53, interacts with and inactivates p63 and p73 (ref. 12), leading to 
increased tumor development41. p53 cannot tetramerize with either 
p63 or p73, and the interaction between mutant p53 and its fam-
ily members is mediated by the respective DNA-binding domains. 
Crucially, it was found that mutant-associated conformational 
modification is essential for the occurrence of these interactions42.
Understanding the connection between these misfolding events 
and their biochemical consequences requires a structural mecha-
nism providing a specific mode of interaction. Aggregation of p53 
has been observed before, both in vitro43 and in vivo, as accumu-
lation44 and cytoplasmic retention45 of p53 is a hallmark of many 
tumors. However, amorphous protein aggregation is generally 
regarded as a nonspecific sequestration process. For instance, cyto-
plasmic sequestration of wild-type p53 has been ascribed to the 
inaccessibility of its C-terminal nuclear localization signal46, but, as 
shown by the current study, cytoplasmic accumulation of wild-type 
p53 by mutant aggregation is independent of the nuclear localiza-
tion signal. We here show that mutant p53 aggregation is an ordered 
process, driven by the self-assembly of a short aggregation-prone 
sequence into non-native β-structured molecular assemblies. It is 
the sequence specificity of this self-assembly process that allows the 
recruiting of both wild-type p53 and its homologs into inactive cel-
lular inclusions, thereby providing a single structural mechanism for 
both the dominant-negative effect and gain of function. In addition, 
this mechanism also suggests a driving role for p53 aggregation in 
the accumulation of chaperones observed in many tumors, possibly 
indirectly driving other gain-of-function effects, including synergies 
with Ras hyperactivation and NF-κB activation9. Finally, although 
this was not observed in the current study, it should not be ignored 
that contact mutants and even wild-type p53 might also aggregate 
by the same mechanism in certain tumor contexts. This is very 
plausible, as p53 regulates its own degradation by negative feedback 
and p53 degradation is generally impaired in tumors. In any case, 
in analogy with neurodegeneration, both the stochasticity and dose 
dependence of protein aggregation could explain the variable and 
heterogeneous accumulation observed in human tumors, which in 
turn could contribute to the clonal selection of tumor lines.
In contrast to neurodegeneration, however, the cellular effects of 
p53 aggregation in cancer are associated with events that contribute 
to cell survival and proliferation rather than to cell death. It remains 
to be seen whether other tumor suppressors can also acquire similar 
gain-of-function activities and whether, in addition to the accumu-
lation of genetic lesions, systemic proteostatic aging also contributes 
to cancer.
METhODS
In silico analysis of the aggregation of p53 wild type and mutants. We ana-
lyzed the aggregation propensity of p53 using TANGO47, an algorithm to predict 
aggregation-nucleating sequences in proteins. The effects of cancer mutants on 
the conformational stability of the p53 DNA-binding domain were taken from the 
literature48 or else estimated using the FoldX force field49.
Plasmid construction. The mammalian expression plasmid pCMV-HA-p53, 
encoding HA tag (YPYDVPDYA) in the N terminus of full-length p53, has been 
described elsewhere50. All point mutations were introduced to pCMV-HA-p53  
vector by oligonucleotide primer–based PCR mutagenesis using Pwo DNA 
polymerase (Roche). The pcDNA3-Flag-p53 encoding Flag tag (DYKDDDDK) 
in the N terminus of full-length p53 is commercially available (plasmid 10838, 
Addgene). The mammalian expression plasmid pcDNA3-HA-p73α encoding  
HA tag (YPYDVPDYA) in the N terminus of the full-length TAp73α isoform  
was kindly provided by G. Melino (University of Rome Tor Vergata).  
The pCMV-TAp63α encoding the full-length TAp63α isoform is commercially 
available (OriGene). The transcriptional activity of p53 was examined by  
PG13-luciferase reporter plasmid, which contains 13 contiguous p53 DNA- 
binding sites upstream of the firefly luciferase gene. The pRL-CMV vector 
(Promega), carrying a Renilla luciferase, was used as a control vector.
Cell culture and transient transfection. Human osteosarcoma SaOS-2 (p53-null) 
and U-2 OS (p53 wild type), pharynx carcinoma Detroit 562 (p53-R175H), T-cell 
leukemia 1301 (p53-R282W), brain astrocytoma MOG-G-CCM (p53-R110P), 
bladder carcinoma HT-1376 (p53-P250L), colon adenocarcinoma WiDr (p53-
R273H) and Ramos Burkitt’s lymphoma (p53 I254D) cell lines were all cultured in 
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DMEM supplemented with 10% (v/v) FCS (Gibco), L-glutamine (4 mM), penicillin 
(100 U ml−1) and streptomycin (100 U ml−1). Proliferating cell cultures were main-
tained in a 5% CO2 humidified incubator at 37 °C. Cotransfection of 5 μg pCMV-
HA-p53 and 5 μg pcDNA3-Flag-p53 (or p73 and p63 plasmids) were performed 
using 50 μl of Lipofectamine 2000 (Invitrogen), following the product manual. 
Briefly, cells were seeded at 1 × 106 cells per 10-cm Petri dish (containing gelatin-
coated coverslips for immunofluorescence) and reached 90% confluency before 
transfection. The complex of DNA and Lipofectamine 2000 was prepared in  
1,250 μl DMEM and incubated for 20 min before adding to cells. For luciferase 
assay, the transfections were performed in 6-well plates, and all materials were 
scaled down in proportion. Twenty-four hours after transfection, cells were 
removed from the incubator and examined.
Immunofluorescence staining. The transgenic mouse models used in this study 
have been described elsewhere13. Tissues were fixed in 4% (v/v) formaldehyde, 
dehydrated, embedded in paraffin and sectioned (5 μm). Paraffin-embedded  
tissues were deparaffinized in changes of xylene and rehydrated in decreasing 
concentrations of ethanol. To eliminate fixation-caused autofluorescence, tissue  
sections were incubated in 1 mg ml−1 sodium borohydrate for 30 min. For  
cultured cells, coverslips were rinsed twice with phosphate buffered saline (PBS) 
and fixed with 4% (v/v) paraformaldehyde for 20 min at 21 °C. After being rinsed 
with PBS, cells were permeabilized and blocked with 0.5% (w/v) Triton X-100 
and 2% (w/v) BSA in PBS for 1 h. The primary antibodies for HA tag (anti-HA.11 
mouse monoclonal, Covance), Flag tag (rabbit polyclonal, Abcam), p53 (mouse 
monoclonal, Santa Cruz Biotechnology), Vimentin (mouse monoclonal, Santa 
Cruz Biotechnology), TAp63α (rabbit polyclonal, Santa Cruz Biotechnology) and 
Tap73α (rabbit polyclonal, Abcam) were each diluted 1:150 in blocking buffer and 
incubated for 40 min. The secondary antibodies (goat anti-mouse Alexa594 or 
goat anti-rabbit Alexa488, Invitrogen) were diluted to 1:1,000 and incubated for 
30 min. After staining with DAPI (1:10,000) and Thioflavin T (10 μM), the cov-
erslips were added with antifade reagent (ProLong Gold, Invitrogen) and kept in 
the dark for 24 h. Images were acquired with a confocal fluorescence microscope 
(Ez-c1, Nikon).
Electrophoresis and western blot. SaOS-2 cells were rinsed with ice-cold 20 mM 
Tris-HCl, 150 mM NaCl, pH 7.4 (TBS) and lysed with 18mM 3-[(3-cholamidopro-
pyl)dimethylammonio]-1- propanesulfonic acid (CHAPS) in TBS with DNase and 
protease inhibitors for 30 min at 21 °C. Whole-cell lysate was fractionated by both 
SDS-PAGE (NuPAGE system, Invitrogen) and BN-PAGE (NativePAGE system, 
Invitrogen) following the product manuals. For SDS-PAGE, sample was denatured 
at 95 °C for 10 min in the presence of 2% SDS and then fractionated by 10% Bis-Tris 
gels in MES-SDS running buffer (0.1% SDS, 50 mM MES and 50 mM Tris-Base). 
For BN-PAGE, cell lysate was added with 20% glycerol and 5 mM Coomassie G-250 
before loading onto 3–12% Novex Bis-Tris gradient gels. The electrophoresis was 
performed in a running buffer containing 50 mM BisTris and 50 mM Tricine  
(plus 0.004% Coomassie G-250 in cathode buffer) under fixed voltage (100 V)  
at 21 °C for 120 min. Proteins were transferred onto polyvinylidene fluoride 
 membranes and stained with Coomassie G-250 to show molecular-weight  
markers (NativeMark, Invitrogen). After fixation with 8% acetic acid for 20 min, 
the  polyvinylidene fluoride membranes were air dried and destained with 100% 
methanol. Membranes were blocked overnight with 4% BSA in TBS at 4 °C before 
immunoblotting. To detect HA or Flag tagged p53, p63 or p73 on the membrane, 
the primary antibody (anti-HA.11, Covance) was diluted to 1:1,000 in  blocking 
buffer and incubated for 1 h at 21 °C. After three rinses with TBS containing  
0.1% Tween-20, the membrane was stained with horseradish peroxidase  
(HRP)-conjugated goat anti-mouse IgG (Promega) and visualized with 
 electrochemical luminescence system. After the irreversible inactivation of HRP  
by sodium azide (NaN3), the membrane was probed with rabbit anti-Flag and  
HRP-conjugated goat anti-rabbit antibodies to detect Flag-tagged wild-type p53. 
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